FDA Daraxonrasib coverage for business development, investment, and market access teams
Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
Daraxonrasib Doubles Survival in Pancreatic Cancer: What Pharma Teams Need to Know
Revolution Medicine Pancreatic Cancer: Demand Surge Strains Daraxonrasib Access
Friday Five: Key Regulatory Updates in Pharma
FDA Approves Expanded Access for Daraxonrasib in Pancreatic Cancer
Five Key Regulatory Updates to Watch at ASCO
First RAS Inhibitor Extends Survival in Metastatic Pancreatic Cancer